File:Images large 10.1177 1753465816661091-fig1.jpg
Original file (901 × 683 pixels, file size: 112 KB, MIME type: image/jpeg)
Summary
Description |
English: Figure 1. Mechanism of action of nivolumab.
The TCR signaling pathway is a major component of immune defense against tumors. Under normal circumstances, TCR recognition of the MHC on APCs will trigger a cascade of events causing activation of T cells and thus immune response against tumor cells. This signal is inhibited by tumor cells with activation of the PD-1/PD-L1 inhibitor co-signaling pathway, which ameliorates T-cell activation. Nivolumab acts by binding onto the PD-L1 on T cells, thus preventing inhibitor co-signaling and restoring T-cell activation. APC, antigen presenting cell; MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1, programmed death-1 ligand; TCR, T-cell receptor. |
Date | |
Source | https://journals.sagepub.com/doi/10.1177/1753465816661091 |
Author | Joline S. J. Lim , Ross A. Soo |
Licensing
This file was uploaded with UploadWizard.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 20:25, 25 March 2024 | 901 × 683 (112 KB) | Ozzie10aaaa (talk | contribs) | Uploaded a work by Joline S. J. Lim , Ross A. Soo from https://journals.sagepub.com/doi/10.1177/1753465816661091 with UploadWizard |
You cannot overwrite this file.
File usage
There are no pages that use this file.